Gene and cell therapy strategy shaped by scalable manufacturing, broader treatment access, CAR-T expansion, and AI-enabled operations

Cell and Gene Therapy Strategic Roundup | Sep 1 – Oct 6, 2026

Gene and cell therapy competition is shifting beyond efficacy. Durability,…


Lucid Diligence Brief - Tech

Basecamp Research $140M Series C: The Translation Test | Lucid Diligence Brief

This Lucid Diligence Brief examines Basecamp Research’s $140M Series C and…


Gene and cell therapy strategy shaped by scalable manufacturing, broader treatment access, CAR-T expansion, and AI-enabled operations

Cell and Gene Therapy Strategic Roundup | Jul 29 – Aug 31, 2026

Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…


Lucid Diligence Brief - BioPharma

Insulinova Partners with Ospedale San Raffaele | Lucid Diligence Brief

Avaí Bio and Insulinova Test Encapsulated Beta Cells With San Raffaele as…


Gene and cell therapy strategy shaped by scalable manufacturing, broader treatment access, CAR-T expansion, and AI-enabled operations

Cell and Gene Therapy Strategic Roundup | June 24–July 29, 2026

Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…


Endocrinology Strategic Roundup

Endocrinology Strategic Roundup | June 23–July 20, 2026

Strategic Developments and Competitive Shifts in Endocrinology Coverage Period:…


Lucid Diligence Brief - BioPharma

United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief

United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…


Lucid Diligence Brief - BioPharma

Merck KGaA Bio-Techne Deal | Lucid Diligence Brief

Merck KGaA’s US$11.3bn Bio-Techne acquisition tests workflow depth, integration…


Lucid Diligence Brief - BioPharma

Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief

Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…


LucidWargames_simulation

In Vivo CAR-T: Stress-Testing the Lilly–Kelonia Deal with AI-Powered Wargaming

Produced with LucidWargames, part of the LucidQuest ecosystem. AI-enabled…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash

Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…


AACR 2026 oncology conference preview covering precision cancer therapies, liquid biopsy, genomics and artificial intelligence.

AACR 2026 Preview: Key Developments in Oncology and AI

AACR 2026 at a glance AACR 2026 in San Diego highlights emerging developments…


Privacy Preference Center